Effect of nalbuphine on cardiac electrophysiology in patients undergoing transurethral ureteroscopic lithotripsy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200065520

Enrollment

Unknown

Registered

2022-11-08

Start date

2022-11-08

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ureteral calculus

Interventions

Group N1:Intravenous injection of 0.2mg/kg nalbuphine

Group D (saline control group):Intravenous saline injection 10ml

Group N2:Intravenous injection of 0.3mg/kg nalbuphine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: normal preoperative cardiopulmonary function, ECG and electrolytes; HR-corrected QT interval (QTc interval) <440 ms; no neurological and psychological related diseases; no history of nalbuphine or other opioid allergy; consent to cooperate with this study.

Exclusion criteria

Exclusion criteria: Exclusion criteria: patient refusal to participate; preoperative electrolyte abnormalities; preoperative ECG suggestive of bradycardia, conduction block, or other arrhythmias; use of drugs that prolong the QT interval (e.g., antiarrhythmics, beta-blockers, antidepressants, phenothiazines, etc.); previous coronary artery disease and other cardiovascular diseases.

Design outcomes

Primary

Measure	Time frame
QT interval;QTc interval;Tp-e interval;Tp-e/QT;	—

Secondary

Measure	Time frame
Mean arterial pressure;Heart rate;	—

Countries

China

Contacts

Public ContactDeng Ju

The First People's Hospital of Fuquan

752817327@qq.com+86 15329666826

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026